

VitaDAO Launches Second IPT: Tokenizing the Artan Bio IP-NFT



Introduction

VitaDAO is thrilled to announce the launch of its second IP Token (IPT) following the successful launch of VITA-FAST last summer. This time, we have tokenized the Artan Bio IP-NFT, a cutting-edge gene therapy project led by top-tier biotech executives with a proven track record of advancing drug development platforms into human clinical trials.

Opportunity

The VitaDAO community now has the exclusive opportunity to support Artan Bio through the crowdsale of the IPT. This initiative allows members to:

- Participate in the governance of the IP
- Influence research priorities
- Decide on the allocation of funds

Project Overview

Artan Bio focuses on gene therapies targeting aging-related genetic factors. The goal is to develop therapeutic candidates that could potentially suppress mutations driving aging. This research is at an early stage, requiring extensive pre-clinical and clinical testing to ensure safety and efficacy.

Community-Driven Model

By decentralizing funding and intellectual property ownership, VitaDAO empowers its community to drive research forward. This model aims to democratize access to cutting-edge therapies, fostering transparent, inclusive, and equitable medical innovation.

VITA-FAST Success (First VitaDAO IPT)

The funding process for the VITA-FAST project was managed by VitaDAO and a massive success with 1700% oversubscription. This remarkable achievement highlights the public's interest in longevity projects and demonstrates the feasibility of VitaDAO's technology. It is a testament to how an improved liquidity system can drive funding for specific projects within the VitaDAO ecosystem.

Key Milestones

- Initial funding through VitaDAO's Sponsored Research Agreement (SRA)
- Design and validation of the engineered suppressor system ([VDP-103](#)) in cells
- Ongoing development and validation in animal models
- Establishing a development candidate for clinical trials

Meet the Team

- [Dr. Michael Torres](#)
 - PhD in Cancer Biology, UT-Southwestern, Dallas
 - Co-founder of ReCode Therapeutics (secured over \$300M funding)
 - CEO of CrossBridge Bio, focusing on next-gen dual payload antibody-drug conjugates
- [Dr. Anthony Schwartz](#)
 - Founder of 15 startups in autoimmune diseases and cancer
 - VitaDAO Entrepreneur in Residence
 - Lecturer at Johns Hopkins
 - Project Manager for Artan Bio

Learn More

For additional details about the project and tokenomics, visit: [VitaDAO Project](#). To understand more about the research, explore this [blog post](#).

Watch Michael & Anthony's presentation at DeSci Berlin for insights on VitaRNA: [Watch Here](#)

Join Us!

By pooling resources and brainpower, we can work towards breakthrough solutions that could one day result in longevity for all.

Participate in the crowdsale: [Crowdsale Link](#)

